Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Agonistic action on which of the following adrenergic
receptors located on ciliary epithelial cells reduces
aqueous secretion:
A. β1 receptor
B. β2 receptor
C. α1 receptor
D. α2 receptor
by

1 Answer

Answer :

D. α2 receptor
by

Related questions

Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor

Last Answer : D. α2 receptor

The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Description : Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors

Last Answer : Answer : A

Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Description : Astimulatory G-protein transduces the signals from (A) α1-and β1-adrenergic receptors (B) α2-and β2-adrenergic receptors (C) α1-and α2-adrenergic receptors (D) β1-and β2-adrenergic receptors

Last Answer : Answer : D

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally blocks α1 and α2 adrenoceptors C. It is the most potent α blocker D. It has no additional β adrenergic blocking property

Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property

Last Answer : A. It produces rapid and short lasting α-adrenergic blockade

Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation

Last Answer : C. Agonistic action on vascular α2 adrenergic receptors

Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels C. Blocking adrenergic action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation

Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors

Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Description : Neostigmine is preferred over physostigmine for treating myasthenia gravis because: A. It is better absorbed orally B. It has longer duration of action C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate D. It penetrates blood-brain barrier

Last Answer : C. It has additional direct agonistic action on nicotinic receptors at the muscle end plate

The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Description : The following sympathomimetic amine has agonistic action on α 1 + α 2 + β 1 + β 3 adrenoceptors, but not on β 2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine

Last Answer : B. Noradrenaline

Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location

Last Answer : C. Transducer pathway of response effectuation

Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β 1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol

Last Answer : B. Dobutamine

The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Description : Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade

Last Answer : A. More potent β adrenergic blocking than α blocking activity

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability

Last Answer : A. It does not activate peripheral dopaminergic receptors

Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Description : Dopaminergic D1 and D2 as well as adrenergic α and β 1, but not β 2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine

Last Answer : A. Dopamine

The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists

Last Answer : B. Adrenergic α1 antagonists

Muscarinic cholinergic receptors: A. Are located only on parasympathetically innervated effector cells B. Mediate responses by opening an intrinsic Na+ ion channel C. Are present on vascular endothelium which has no cholinergic nerve supply D. Predominate in the autonomic ganglia

Description : Muscarinic cholinergic receptors: A. Are located only on parasympathetically innervated effector cells B. Mediate responses by opening an intrinsic Na+ ion channel C. Are present on vascular endothelium which has no cholinergic nerve supply D. Predominate in the autonomic ganglia

Last Answer : C. Are present on vascular endothelium which has no cholinergic nerve supply

Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Description : Betaxolol differs from timolol in that it: A. Is a β1 selective blocker B. Is more efficacious in glaucoma C. Produces less ocular side effects D. Is longer acting

Last Answer : A. Is a β1 selective blocker

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Description : The principal process which terminates the action of noradrenaline released from adrenergic nerve ending is: A. Degradation by MAO B. Methylation by COMT C. Axonal uptake D. Extraneuronal uptake

Last Answer : C. Axonal uptake

Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Description : Esmolol has the following features except: A. Rapidly developing, shortlasting β adrenergic blockade B. Cardioselectivity of action C. Intrinsic sympathomimetic activity D. Suitability for intraoperative use

Last Answer : C. Intrinsic sympathomimetic activity

Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Description : Ephedrine is similar to adrenaline in the following feature: A. Potency B. Inability to penetrate blood-brain barrier C. Duration of action D. Producing both α and β adrenergic effects

Last Answer : D. Producing both α and β adrenergic effects

The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Description : The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Last Answer : B. Intestinal relaxation

Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Description : Pyridostigmine differs from neostigmine in that: A. It is more potent orally B. It is longer acting C. It produces less muscarinic side effects D. It does not have any direct action on NM receptors

Last Answer : B. It is longer acting

The following action of adrenaline is not mediated by β receptors: A. Dilatation of blood vessels B. Dilatation of pupil C. Bronchodilation D. Renin release from kidney

Description : The following action of adrenaline is not mediated by β receptors: A. Dilatation of blood vessels B. Dilatation of pupil C. Bronchodilation D. Renin release from kidney

Last Answer : B. Dilatation of pupil

The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Description : The following action of adrenaline is mediated by both α and β receptors producing the same directional effect: A. Cardiac stimulation B. Intestinal relaxation C. Dilatation of pupil D. Bronchodilatation

Last Answer : B. Intestinal relaxation

What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Description : What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Last Answer : C. It improves penile tumescence in men with erectile dysfunction

What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Description : What is true of sildenafil: A. It enhances sexual enjoyment in normal men B. It delays ejaculation C. It improves penile tumescence in men with erectile dysfunction D. It blocks cavernosal α2 adrenoceptors

Last Answer : C. It improves penile tumescence in men with erectile dysfunction

Which of the following organs is innervated only by parasympathetic nerves: A. Iris muscles B. Ciliary muscle C. Sweat glands D. Splenic capsule

Description : Which of the following organs is innervated only by parasympathetic nerves: A. Iris muscles B. Ciliary musclele C. Sweat glands D. Splenic capsu

Last Answer : B. Ciliary musclele

Which of the following organs is innervated only by parasympathetic nerves: A. Iris muscles B. Ciliary muscle C. Sweat glands D. Splenic capsule

Description : Which of the following organs is innervated only by parasympathetic nerves: A. Iris muscles B. Ciliary muscle C. Sweat glands D. Splenic capsule

Last Answer : B. Ciliary muscle

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : C. Acebutolol

In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Description : In a patient of myocardial infarction, β adrenergic blockers are used with the following aim/aims: A. To reduce the incidence of reinfarction B. To prevent cardiac arrhythmias C. To limit size of the infarct D. All of the above

Last Answer : D. All of the above

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol

Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Description : Select the ultrashort acting cardioselective β adrenergic blocker: A. Bisoprolol B. Timolol C. Sotalol D. Esmolol

Last Answer : D. Esmolol

β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Description : β-adrenergic blockers are indicated in the following conditions except: A. Hypertrophic cardiomyopathy B. Congestive heart failure C. Vasospastic angina pectoris D. Dissecting aortic aneurysm

Last Answer : C. Vasospastic angina pectoris

Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Description : Sildenafil is contraindicated in patients taking the following class of drugs: A. α-adrenergic blockers B. β-adrenergic blockers C. Organic nitrates D. Angiotensin converting enzyme inhibitors

Last Answer : C. Organic nitrates

The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Description : The drug which produces vasoconstriction despite being an α adrenergic blocker is: A. Phenoxybenzamine B. Ergotamine C. Dihydroergotoxine D. Tolazoline

Last Answer : B. Ergotamine

The nonselective α adrenergic blockers produce the following actions except: A. Postural hypotension B. Bradycardia C. Miosis D. Inhibition of ejaculation

Description : The nonselective α adrenergic blockers produce the following actions except: A. Postural hypotension B. Bradycardia C. Miosis D. Inhibition of ejaculation

Last Answer : B. Bradycardia

Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Description : Tyramine induces release of noradrenaline from adrenergic nerve endings: A. By depolarizing the axonal membrane B. By mobilizing Ca2+ C. By a nonexocytotic process D. Only in the presence of MAO inhibitors

Last Answer : C. By a nonexocytotic process

In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Description : In hyperthyroidism, β adrenergic blockers are used: A. To induce euthyroid state B. As definitive therapy C. For rapid control of certain symptoms while awaiting response to carbimazole D. To reduce basal metabolic rate

Last Answer : C. For rapid control of certain symptoms while awaiting response to carbimazole

Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Description : Select the β -adrenergic blocker that has additional α 1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol

Last Answer : A. Carvedilol

Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Description : Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol Select the β adrenergic blocker that is primarily eliminated unchanged by renal excretion: A. Propranolol B. Metoprolol C. Esmolol D. Atenolol

Last Answer : D. Atenolol